Published on: 13 April 2021 FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications more
Published on: 12 April 2021 Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% more
